The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth.

Oncotarget · 2018 · PMC6145692 · PMID 30237855

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Most strikingly, genes downregulated by JIB-04 treatment and also normally upregulated by EWS/Fli1 showed highly significant enrichment of processes related to cell proliferation (Figure 4B , middle panel).

also in 132,142 other papers

an overall trendno p-value reported

This revealed positive and negative regulation of subsets of both EWS/Fli1-induced and EWS/Fli1-repressed genes, with an overall trend toward repression of EWS/Fli1-induced genes, and induction of EWS/Fli1-repressed genes (Figure 4A ).

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.